Uillted States Patent [19] [11] Patent Number: 5,011,843 Shell [45] Date of Patent: Apr

UIllted States Patent [19] [11] Patent Number: 5,011,843 Shell [45] Date of Patent: Apr. 30, 1991 [54] TREATMENT OF GLAUCOMA USING [58] Field of Search ....................................... .. 514/259 PHOSPHODIESTERASE INHIBITORS l J F . Primary Examiner-Stan ey . riedman [75] Inventor: John W. Shell, Hillsborough, Calif. Assistant Examiner_zohreh A. Fay [73] Assignee: Iolab Corporation, Claremont, Calif. Attorney, Agent, or Firm-Benjamin F. Lambert [21] Appl. No.: 531,729 [57] ABSTRACI' [22] Filed: J‘m- 1’ 1990 Lowering of intraocular pressure, e.g. in the treatment _ . of glaucoma is carried out by administering a phospho Related U-S- Application Data diesterase inhibitor to a patient. Particular ophthalmic [62] Division of Sn‘. No, 200,309, May 31, 1933, pat‘ No, . pharmaceutical compositions are disclosed for topical 4,975,428. application to the eye. [51] Int. Cl.’ .......................................... .. A61K 31/505 [52] US. Cl. .................................................. .. 514/259 2 Claims, No Drawings 5,011,843 I , 2’ R3 may be H, C1.6alkyl, C3.6branched-chain alkyl or TREATMENT OF GLAUCOMA USING C3.6cycloalkyl, and when X is 2H, R3 may also be PHOSPHODIESTERASE INHIBITORS acyl, arylacyl or alkanesulfonyl; This is a division of application Ser. No. 200,809, ?led 5 R4 may be H, halogen, Cmalkyl, C3_6branched-chain May 31, 1988, now US. Pat. No. 4,975,428. alkyl, C3.6cycloalkyl or C1-6alkoxy; At the Association for Research in Vision and Oph R5 and R6 may each be H, C1-6alkyl, C3.6branched thalmology Meeting May 1-6, 1988, Poster No. 22 was chain alkyl or C3-6cycloalkyl; and entitled “Ocular Hypotension Induced by Grisfolic the dotted line may be a single or double bond between Acid, a Phosphodiesterase Inhibitor” by Hiromu Mis C4 and C5 of the pyridazine ring. hima et al.. Preferred compounds of formula (I) are those BACKGROUND OF THE INVENTION _ wherein R1 is CH3, R2 and R3 are hydrogen, R‘, R5 and In the sympathetic nervous system cascade, adeno R6 are hydrogen or CH3, X is O and the pyridazinone sine triphosphate (ATP) is converted by action of a ring is attached at C-7 of the benzoxazine ring. A partic catecholamine, such as epinephrine, to cyclic adenosine ular compound of formula (I) is 6-[3,4-dihydro-3-oxo monophosphate (cAMP) which is then converted to l,4[2H]-benzoxazine-7-yl]-2,3,4,5-tetrahydro-5-methyl 5’-adenosine monophosphate (5'-AMP) by the action of the enzyme phosphodiesterase (PDE). This cascade pyridazin~3~one known as ORF 22,867 and having the results in physiological responses to environmental following formula (Ia): stresses, the so-called adrenergic effects. PDE inhibitors include papaverine and the xanthines (Ia) such as theophylline and caffeine. PDE inhibitors are used in cosmetics as set forth in US. Pat. No. 3,978,213. Theophylline as well as other PDE inhibitors are used as a bronchodilator for relief of the symptoms of asthma. Glaucoma is an ocular disorder most often character ized by increased intraocular pressure which, over time, may cause impaired vision or blindness. Treatments include topical agents such as pilocarpine (a cholinomi The above compounds of formula (I) are described in metic drug); timolol maleate (a B-adrenergic receptor US. Pat. No. 4,721,784 to Donald W. Combs, issued blocking agent); epinephrine (an a- and B-adrenergic Jan. 26, 1988 which is hereby incorporated by reference receptor agonist); dipivefrin (a prodrug of epinephrine) with respect to synthesis and de?nition of the com and demecarium bromide (a cholineesterase inhibitor). Systemic agents used to treat glaucoma include car pounds. bonic anhydrase inhibitors such as acetazolamide. A second particular group of PDE inhibitors to be An object of the present invention is an effective used in the present invention are quinazolinones of the treatment for glaucoma by providing an agent which following formula (II): lowers intraocular pressure. SUMMARY OF THE INVENTION R90 (11) A treatment for lowering intraocular pressure is pro vided whereby a phosphodiesterase inhibitor is adminis 45 tered to a patient. DETAILED DESCRIPTION OF THE INVENTION Particular PDE inhibitors include compounds of the 50 wherein following formula (I): R7 is hydrogen provided that R7 is hydrogen only when the dotted line linkage represents a saturated bond; R1 / 40 (I) R8 is hydrogen, lower alkyl, cycloalkyl having 4-8 6 55 carbon atoms, cycloalkylalkyl wherein the cycloalkyl R O \ N ‘ group has 4-8 carbon atoms and the alkyl group has 115T N’ \RZ l-3 carbon atoms, haloalkyl having l-3 halogen % atoms and l-4 carbon atoms, norbornyl and norbor X N 60 nylmethyl; "13 R‘ R9 is lower alkyl, and the dotted line linkage represents a saturated bond wherein XmaybeHandHorO; or a double bond. Rl may be H, C1.6alkyl, Cygbranched-chain alkyl or 65 A preferred compound of formula (II) is 5,6-dime C3.6cyc1oalkyl; thoxy-4-methyl-2[lH]-quinazolinone known as ORF R2 may be H, C1.6alkyl, CMbranched-chain alkyl, C3. 16,600 or bemarinone and having the following formula écycloalkyl or C2-6alkenyl; (Ila): 5,011,843 4 from the supernatant and quantitated by liquid scintilla H3CO CH3 (H3) tion spectrometry. The results are expressed as the IC50 which is the concentration (nM) of compound required N to inhibit 50% of the cyclic nucleotide phosphodiester ase activity. In vivo lowering of intraocular pressure may be tested by the method of Goldmann Aplanation Tonom etry, Schiotz Tonometry or other systems such as the The above compounds of formula (II) are described in Tono-Pen or the pneumotonometer. U.S. Pat. No. 4,490,374 to Victor T. Bandurco et a1. 10 issued Dec. 25, 1984 which is hereby incorporated by EXAMPLE 1 reference with respect to synthesis and de?nition of the To test PDE inhibitors as agents for lowering intra compounds. , ocular pressure, normotensive and hypertensive rabbits Other speci?c PDE inhibitors to be used in the pres were used. Active agents were formulated by preparing ent invention include those described by el Allaf in 5 a sterile suspension of the agent at a 2% by weight Arch. Int. Physiol. Biochim, Nov. 1984, 92(4) S 69-79 concentration in aqueous saline. Each preparation was and by W. S. Hillis in Eur. Heart, J., Dec. 1982, 3 Suppl coded and tested in conjunction with a placebo which is D, 97-101, including carbazeran. randomly applied to the normotensive eye. In the hy Systemic formulations of PDE inhibitors are pre pertensive rabbit, only one eye will be used. Intraocular pared as known in the art, e.g. as set forth in US. Pat. pressure is determined by either the Tono-Pen hand No. 4,721,784. held tonometer made by Intermedics Intraocular of For topical application, the PDE inhibitor may be formulated by preparing a solution or suspension which Pasadena, Calif. or a pneumotonometer with topical may be preserved with a preservative such as benzalko anesthetic. Data is analyzed with the paired T-test. nium chloride and formulated with aids such as polyvi Using the above procedure, ORF 16,600 test results nyl alcohol or methyl cellulose. The PDE inhibition were as shown below in Table I: may be used in an amount of 0.05 to 2.0% by weight of TABLE I the ophthalmic composition. The suspension formula Hr Drug Placebo Delta p tion may be similar to that of Dexacidin made by Iolab Pharmaceuticals of Claremont, Calif. with 6 mg/mL 30 0 20.3 i 2.5 20.0 i 2.9 +0.3 .39 1 17.0 i 2.8 17.8 i 2.3 —0.8 .08 hydropropylmethylcellulose, 8.5 mg/mL sodium chlo 2 17.1 3: 3.3 17.2 i 2.0 —0.1 .86 ride, 0.5 mg/mL of Polysorbate 20 and 0.04 mg/rnL 3 19.7 i 2.7 20.0 i 2.6 -0.3 .47 benzalkonium chloride with water q.s. and HCl to ad 4 20.3 i- 3.1 20.5 i 1.8 -O.2 .79 just the PH to 5.3 to 5.7. Solubility may be enhanced by formulation with a nonionic or anionic surfactant, par The relatively weak potency of ORF 16,600 re?ected ticularly a nonionic surfactant, such as Pluronic F-68 or by complexation with a cyclodextrin. in Table 1 appears to be caused by a lack of solubility Drug delivery systems for use in the present inven may be enhanced by increasing the solubility of the tion include eye drops, ointments and controlled release drug, eg by complexing with a B-cyclodextrin or a systems such as Ocusert system from Alza Corporation 40 poloxomer. of Palo Alto, Calif, and those described in my co-pend What is claimed is: ing application, U.S. Ser. No. 61,591, filed June 15, 1. A method of lowering intraocular pressure in a 1987, which is equivalent to EPO Publication No. mammal which comprises administering to the eye of 251,680, published Feb. 24, 1988. said mammal a pharmaceutical composition comprising The dosage to be used will depend on the severity of 45 a therapeutically effective amount of a phosphodiester the patient’s condition, the potency of the particular ase inhibitor of the following formula: PDE inhibitor and the formulation used. For example, a potent PDE inhibitor may be used at a high dose with, however, a controlled release system as described above. 50 PDE inhibitory activity may be determined in vitro in accordance with the method of W. J. Thompson, et al., inAdv. Cycli. Nucleotide Res. Ed. G. Brooker, et al., N E0 Vol. 10, pp. 69-92 (1979).

Load more